セロトニン-2A受容体 (5-HT2AR) 調節器の差異的効果の分子動態研究
Jordy Peeters1, Dimitri De Bundel2, Kenno Vanommeslaeghe1
1Department of Analytical Chemistry, Applied Chemometrics and Molecular Modelling (FABI), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
PLoS computational biology
|September 3, 2025
まとめ
セロトニン2A受容体 (5-HT2AR) の適度な活性化により,幻覚なしに抗うつ薬の効果が得られる. しかし過剰な活性化により 幻覚が起こり 薬剤の治療期間の狭い可能性を示唆します
科学分野:
- 神経科学
- 薬理学について
- コンピュータ化学
背景:
- セロトニン2A受容体 (5-HT2AR) は,新しい抗うつ薬の主要な標的であり,特に急速発症または治療に抵抗するうつ病の標的である.
- 5HT2ARの活性化に伴う幻覚誘発の可能性は大きな障害です.
- 部分的アゴニストは,精神的模倣の副作用のない抗うつ効果について調査されています.
研究 の 目的:
- 様々なリガンドによる差異的な5-HT2AR活性化の基礎となる原子化メカニズムを解明する.
- 5-HT2ARのリガンド依存構造を特定する.
- 幻覚に対する抗うつ薬の構造的根拠を理解するために
主な方法:
- 5-HT2ARで原子分子動力学 (MD) のシミュレーションを行いました.
- シミュレーションには,抗精神病薬,潜在的非幻覚剤,幻覚剤の結合が含まれていました.
- リガンド結合受容体の形状を分析した.
主要な成果:
- 控えめな5-HT2AR活性化が抗うつ剤効果と相関していることが示唆されています.
- 幻覚は 過剰な受容体の活性化に起因する
- 異なるリガンド依存構造が特定された.
結論:
- 5HT2ARの適度な活性化により,うつ病に対する治療効果が認められる.
- 過剰な活性化により 幻覚が起こり 治療の窓が狭いのです
- 弱い部分的アゴニストは より安全な抗うつ薬の開発戦略を提供する.
関連する概念動画
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
563
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
563
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
293
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
293


